In a recent interview with Healthcare Brew, Laura Bray discussed how the Iran war could create new vulnerabilities across the global pharmaceutical supply chain, adding pressure to a system already struggling with ongoing drug shortages. The article highlights concerns around the availability of generic medicines, which are especially vulnerable because they are produced on extremely thin margins and rely on complex global manufacturing and transportation networks.
Laura explained that disruptions tied to geopolitical conflict — including rising transportation costs, manufacturing slowdowns, raw material shortages, and shipping delays — can quickly ripple across the healthcare system and threaten access to essential medications. She also cautioned against stockpiling medications or changing purchasing behavior out of fear, noting that sudden spikes in demand can unintentionally worsen shortages and create additional strain throughout the supply chain.
““What could cause challenges is people buying differently than they did for fear of those changes, and that could be immediate and severe,””
Instead, Laura encouraged health systems and providers to proactively communicate with manufacturers and supply chain partners about resiliency planning, including participation in programs that help strengthen buffer supplies of vulnerable medicines. The article reinforces that drug shortages are not isolated incidents, but symptoms of a fragile and interconnected system that requires greater transparency, coordination, and long-term investment to protect patient care.
If you need help navigating any drug shortage, our Drug Shortage Hotline remains open to support patients and providers impacted by all supply chain disruptions.
Drug shortages are not isolated events. They are part of a system that urgently needs greater coordination and resilience.
Read The Full Article: https://www.healthcare-brew.com/stories/2026/04/22/iran-war-pharmaceuticals-supply-chain
